GemPharmatech Co (SHSE:688046) Payments of Debt: ¥-189.7 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688046 GemPharmatech Co Ltd SHSE:688046
83 GF Score
Price ¥38.60
GF Value ¥19.34
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is GemPharmatech Co Payments of Debt?

GemPharmatech Co SHSE:688046 -2.33% 83 Payments of Debt is ¥-189.7 Mil as of Mar. 2026. GuruFocus rates SHSE:688046 with a GF Score™ of 83/100 and a GF Value™ of ¥19.34 (Significantly Overvalued). The stock has 10 warning signs investors should review.

GemPharmatech Co's Payments of Debt for the three months ended in Mar. 2026 was ¥-58.4 Mil.

GemPharmatech Co's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-189.7 Mil.

GemPharmatech Co Payments of Debt Related Terms

GemPharmatech Co Payments of Debt Historical Data

* Premium members only.

The historical data trend for GemPharmatech Co's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GemPharmatech Co Payments of Debt Chart

GemPharmatech Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial -10.69 -25.00 -21.99 -86.00 -199.21

GemPharmatech Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -67.95 -0.00 -19.95 -111.31 -58.42
SHSE:688046
83GF Score
GemPharmatech Co Ltd SHSE:688046
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GemPharmatech Co Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-189.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of ¥-189.7 Mil mean?
GemPharmatech Co (SHSE:688046) has a Payments of Debt of ¥-189.7 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on GemPharmatech Co and its competitors.
Is GemPharmatech Co's Payments of Debt too high?
GemPharmatech Co's current Payments of Debt is ¥-189.7 Mil. Overall, GemPharmatech Co has a GF Score™ of 83/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GemPharmatech Co's Payments of Debt compare to VRTX and REGN?
GemPharmatech Co's Payments of Debt of ¥-189.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on GemPharmatech Co and its competitors. GemPharmatech Co's current Payments of Debt is ¥-189.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GemPharmatech Co stock overvalued right now?
Based on GuruFocus' analysis, GemPharmatech Co (SHSE:688046) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥19.34, compared to a current price of ¥38.60 — trading 99.6% above its estimated fair value. The current Payments of Debt is ¥-189.7 Mil. GemPharmatech Co's overall GF Score™ is 83/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For GemPharmatech Co (SHSE:688046), the current Payments of Debt is ¥-189.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GemPharmatech Co (SHSE:688046) Overvalued in 2026?

Based on GuruFocus' analysis, GemPharmatech Co stock appears to be overvalued. The current stock price of ¥38.60 is trading 99.6% above its estimated GF Value™ of ¥19.34. GuruFocus considers GemPharmatech Co to be Significantly Overvalued.

Key valuation signals for SHSE:688046:

  • Payments of Debt: ¥-189.7 Mil
  • GF Value™: ¥19.34 vs. price of ¥38.60 (99.6% above fair value)
  • GF Score™: 83/100 with 10 warning signs

No single metric tells the full story. See the SHSE:688046 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GemPharmatech Co Business Description

Address No. 12, Xuefu Road, Jiangbei New District, Jiangsu Province, Nanjing, CHN, 210032
GemPharmatech Co Ltd is a provider of genetically engineered mouse models and services to preclinical research and development communities. The company develops mouse models with independent intellectual property rights based on technical platforms such as gene editing, stem cells, phenotypic analysis, efficacy analysis, and sterile animals, and carries out one-stop services such as model customization, customized breeding, and functional efficacy analysis.
83GF Score

Get the complete analysis for SHSE:688046

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥38.60
Price
¥19.34
GF Value